Funda Meric-Bernstam, MD, co-chair of the 2021 Cholangiocarcinoma Foundation Annual Conference, gives her insight on immunotherapies in cholangiocarcinoma.
Funda Meric-Bernstam, MD, chair of the Department of Investigational Cancer Therapeutics and medical director of the Institute for Personalized Cancer Therapy at The University of Texas MD Anderson Cancer Center, and co-chair of the 2021 Cholangiocarcinoma Foundation Annual Conference, gives her insight on immunotherapies in cholangiocarcinoma.
Transcript
One session focuses on immuno-oncology, a growing class of therapies for cholangiocarcinoma. What are some recent advances you think may come up in this discussion?
We're so excited about immunotherapy in general, and of course immunotherapy has really revolutionized the care of multiple diseases. These are diseases of what we call "hot" diseases, where we think that the tumor is more immunogenic, which means the tumor has features that the body is likely to perceive as not normal and more likely to mount an immune response to it with just a little bit of help. Chelangiocarcinoma is not one of those diseases where we think is readily going to be benefit from immunotherapy across the board in all patients. Thus, we're really trying to figure out how we identify the patients that would benefit from just checkpoint inhibitors. That is some patients, but all in all, not most patients. But also, there's many different combination therapies in development, and which one of those combination therapies are likely to be fruitful? And how do we determine that? What is the path forward, and what are the logical combinations should we be exploring, and what are the new technologies being developed in the space? [We're] looking at different cellular therapy strategies, looking at novel bispecific strategies, looking at strategies such as vaccines. I think we're going to be covering a variety of different perspectives, so again, that should be very interesting session.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More